Luminex Corp. (NASDAQ:LMNX) shares rose 3.3% during mid-day trading on Wednesday . The company traded as high as $21.03 and last traded at $20.98, with a volume of 124,673 shares traded. The stock had previously closed at $20.30.

LMNX has been the subject of a number of research reports. Zacks Investment Research upgraded Luminex Corp. from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Friday, April 15th. Leerink Swann restated a “hold” rating and issued a $22.00 price target on shares of Luminex Corp. in a research note on Tuesday, May 3rd. Finally, Piper Jaffray Cos. restated a “hold” rating and issued a $20.00 price target (up from $19.00) on shares of Luminex Corp. in a research note on Tuesday, May 3rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $20.83.

The firm has a market capitalization of $906.67 million and a P/E ratio of 23.51. The stock’s 50 day moving average price is $20.10 and its 200-day moving average price is $19.69.

Luminex Corp. (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, May 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.15. The business earned $63 million during the quarter, compared to analyst estimates of $60.98 million. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 earnings per share. Equities analysts anticipate that Luminex Corp. will post $0.67 EPS for the current year.

A number of hedge funds and institutional investors have recently bought and sold shares of the company. EQIS Capital Management increased its position in Luminex Corp. by 883.5% in the fourth quarter. EQIS Capital Management now owns 46,942 shares of the company’s stock worth $1,004,000 after buying an additional 42,169 shares during the period. Russell Frank Co increased its position in Luminex Corp. by 47.1% in the fourth quarter. Russell Frank Co now owns 238,775 shares of the company’s stock worth $5,167,000 after buying an additional 76,444 shares during the period. DIAM Co. Ltd. increased its position in Luminex Corp. by 32.2% in the fourth quarter. DIAM Co. Ltd. now owns 73,009 shares of the company’s stock worth $1,562,000 after buying an additional 17,785 shares during the period. Nationwide Fund Advisors increased its position in Luminex Corp. by 259.4% in the fourth quarter. Nationwide Fund Advisors now owns 105,495 shares of the company’s stock worth $2,257,000 after buying an additional 76,140 shares during the period. Finally, California State Teachers Retirement System increased its position in Luminex Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 79,760 shares of the company’s stock worth $1,706,000 after buying an additional 1,282 shares during the period.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.